ES2131188T3 - Prevencion y tratamiento de citomegalovirus utilizando aminopeptidasa. - Google Patents

Prevencion y tratamiento de citomegalovirus utilizando aminopeptidasa.

Info

Publication number
ES2131188T3
ES2131188T3 ES94906142T ES94906142T ES2131188T3 ES 2131188 T3 ES2131188 T3 ES 2131188T3 ES 94906142 T ES94906142 T ES 94906142T ES 94906142 T ES94906142 T ES 94906142T ES 2131188 T3 ES2131188 T3 ES 2131188T3
Authority
ES
Spain
Prior art keywords
prevention
treatment
cytomegalovirus
aminopeptidase
aminopeptidases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94906142T
Other languages
English (en)
Inventor
John A Zaia
Terrence Giugni
Erna Moller
Cecilia Soderberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2131188T3 publication Critical patent/ES2131188T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3687—Chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

EL INVENTO PROPORCIONA UN METODO PARA LA PREVENCION Y TRATAMIENTO DE LA INFECCION DE CITOMEGALOVIRUS HUMANA (HCMV) QUE COMPRENDE LA ADMINISTRACION A UN PACIENTE QUE NECESITE DEL MISMO DE UNA CANTIDAD DE UNA AMINOPEPTIDASA, UN FRAGMENTO DE UNA AMINOPEPTIDASA, UN INHIBIDOR DE UNA AMINOPEPTIDASA Y/O UN ANTICUERPO CONTRA UNA AMINOPEPTIDASA TERAPEUTICAMENTE EFECTIVA PARA OBTENER DICHA PREVENCION O TRATAMIENTO. EL INVENTO TAMBIEN PROPORCIONA UN METODO PARA ELIMINAR VIRIONES CMV O CELULAS INFECTADAS CMV DE FLUIDOS CORPORALES O MEDULAS OSEAS Y UN METODO Y UNA HERRAMIENTA PARA EL DIAGNOSTICO DE LA INFECCION CMV.
ES94906142T 1993-01-21 1994-01-21 Prevencion y tratamiento de citomegalovirus utilizando aminopeptidasa. Expired - Lifetime ES2131188T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US698293A 1993-01-21 1993-01-21
US9966493A 1993-07-30 1993-07-30

Publications (1)

Publication Number Publication Date
ES2131188T3 true ES2131188T3 (es) 1999-07-16

Family

ID=26676317

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94906142T Expired - Lifetime ES2131188T3 (es) 1993-01-21 1994-01-21 Prevencion y tratamiento de citomegalovirus utilizando aminopeptidasa.

Country Status (11)

Country Link
US (1) US6511662B1 (es)
EP (1) EP0680333B1 (es)
JP (1) JPH08506106A (es)
AT (1) ATE179613T1 (es)
AU (1) AU681115B2 (es)
CA (1) CA2154346A1 (es)
DE (1) DE69418307T2 (es)
DK (1) DK0680333T3 (es)
ES (1) ES2131188T3 (es)
GR (1) GR3030462T3 (es)
WO (1) WO1994016724A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023100A2 (en) * 1998-10-22 2000-04-27 Curagen Corporation Genes and proteins predictive and therapeutic for renal disease and associated disorders
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
GB0803076D0 (en) * 2008-02-20 2008-03-26 Univ Ghent Mucosal Membrane Receptor and uses thereof
SG10201706350PA (en) 2008-07-16 2017-09-28 Inst For Res In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof

Also Published As

Publication number Publication date
DE69418307T2 (de) 1999-11-04
CA2154346A1 (en) 1994-08-04
ATE179613T1 (de) 1999-05-15
EP0680333A1 (en) 1995-11-08
EP0680333B1 (en) 1999-05-06
AU681115B2 (en) 1997-08-21
AU5999194A (en) 1994-08-15
DK0680333T3 (da) 2000-01-03
WO1994016724A1 (en) 1994-08-04
GR3030462T3 (en) 1999-10-29
DE69418307D1 (de) 1999-06-10
JPH08506106A (ja) 1996-07-02
US6511662B1 (en) 2003-01-28

Similar Documents

Publication Publication Date Title
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
EP0831873A4 (en) COMBINATORY THERAPY FOR THE TREATMENT OF HIV AND OTHER VIRAL INFECTIONS
ATE230757T1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
ATE252901T1 (de) Arzneimittel zur behandlung von entzündlichen herzkrankheiten
DE69631157D1 (de) Pharmazeutische Zubereitung zur Verwendung in der Behandlung von Diabetes
BG100455A (en) Hiv protease inhibitors
CA2310888A1 (en) Monoclonal human natural antibodies
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
ATE182271T1 (de) Arzneimittel zur behandlung von krebs, aids und viruserkrankungen
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
ES2131188T3 (es) Prevencion y tratamiento de citomegalovirus utilizando aminopeptidasa.
EP0821965A3 (de) Verwendung von (Meth)arcylsäure-Maleinsäure-Copolymeren zur Verbesserung der Permeabilität der Schleimhaut
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
KR950700761A (ko) 사람 면역결핍 바이러스(HIV) 감염의 예방 및 치료를 위한 재조합 사람 HIV-중화 모노클로날 항체(Recombinant human HIV-neutralizing monoclonal antibodies for prevention and treatment of HIV infection)
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
MA26650A1 (fr) Oxo-thia -azabicyclooctenes, preparations pharmaceutiques les contenant, et leur utilisation pour le traitement et la prophylaxie de maladies infectieuses.
WO1997026880A3 (en) Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
AU9495098A (en) Methods for use of interleukin 4 (il-4) to treat human immunodeficiency virus infection
UA41326C2 (uk) Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань
AU6447690A (en) Method of administering soluble t4 for treatment of human immunodeficiency virus infection
DE4490853D2 (de) Behandlung von (Retro)viralen Erkrankungen sowie Verfahren zur Herstellung einer pharmazeutischen Zubereitung
AU3593095A (en) Method of treatment of human immunodeficiency virus (hiv) infection
DE3883754D1 (de) Mittel zur prophylaxe und behandlung von viralen infektionskrankheiten.
IT1228560B (it) Procedimento per la preparazione su scala industriale di interferon di leucocita umano ad alta purezza e terapeuticamente utile.
NO982151L (no) Hemoregulatoriske forbindelser

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 680333

Country of ref document: ES